PMID- 11482746
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20220311
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 18
IP  - 7
DP  - 2001
TI  - Clinical and economic factors in the treatment of behavioural and psychological 
      symptoms of dementia.
PG  - 527-50
AB  - The prevalence of behavioural and psychological symptoms of dementia (BPSD) 
      exceeds 50%. They cause distress to patients and caregivers, increase resource 
      utilisation of various kinds, and form a high risk for accelerated psychiatric 
      care through institutionalisation. Although evidence for current pharmacological 
      treatment is not strong and the construct of BPSD is still not very clear, future 
      aspects of treatment of BPSD may be positive. If we look at overall success rates 
      of the antipsychotics, the traditional antipsychotics have the highest combined 
      success rate of 63.1%, whereas the novel antipsychotics have an overall success 
      rate of 56.1%. Haloperidol is the drug with the highest success rate of 65.4%, 
      although this drug is associated with parkinsonian adverse drug reactions. Newer 
      antipsychotics show promise in treating BPSD, but more convincing evidence (e.g. 
      from randomised clinical trials) is required. We provide an overview of the 
      clinical, epidemiological and economic aspects of BPSD and a review of the 
      available literature on their pharmacological treatment. Although only 1 
      pharmacoeconomic study has been conducted on BPSD, it seems likely that these 
      manifestations drastically increase the burden of dementia.
FAU - Hemels, M E
AU  - Hemels ME
AD  - Graduate Faculty of Pharmaceutical Sciences, University of Toronto, Ontario, 
      Canada.
FAU - Lanctot, K L
AU  - Lanctot KL
FAU - Iskedjian, M
AU  - Iskedjian M
FAU - Einarson, T R
AU  - Einarson TR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Anticonvulsants)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - Aged
MH  - Anti-Anxiety Agents/therapeutic use
MH  - Anticonvulsants/therapeutic use
MH  - Antidepressive Agents/therapeutic use
MH  - Antipsychotic Agents/therapeutic use
MH  - Cost of Illness
MH  - Dementia/drug therapy/economics/*psychology
MH  - Economics, Pharmaceutical
MH  - Humans
MH  - Mental Disorders/*therapy
RF  - 181
EDAT- 2001/08/03 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/03 10:00
PHST- 2001/08/03 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/03 10:00 [entrez]
AID - 10.2165/00002512-200118070-00006 [doi]
PST - ppublish
SO  - Drugs Aging. 2001;18(7):527-50. doi: 10.2165/00002512-200118070-00006.